Liver disease accounts for two million deaths annually and is responsible for 4% of all
deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related …

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

One quarter of the global population is estimated to have nonalcoholic fatty liver disease
(NAFLD). The incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by …

Hepatocellular carcinoma (HCC), the primary malignancy of hepatocytes, is a diagnosis with
bleak outcome. According to National Cancer Institute's SEER database, the average five …

Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only
in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic …

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …

Non-alcoholic fatty liver disease (NAFLD) is projected to become the leading cause of
hepatocellular carcinoma (HCC) in many countries. Many risk factors for NAFLD are also …

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …